Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
A first-in-human Phase I clinical trial at UC San Diego (NCT05040217) is testing AAV2-BDNF gene therapy in 12 patients with early Alzheimers disease and MCI
Dietary modifications, such as avoiding spicy or acidic foods and eating smaller, more frequent meals, can significantly alleviate symptoms
When you run it indefinitely, you progressively reduce your own receptor sensitivity and the compound stops working while you're still paying for it
This listing is structured to support research procurement teams, institutional buyers, and laboratory environments that require clear product naming, neutral descriptions, and organized receiving procedures
Incorporating IV therapy into the treatment plans can form a vital component of a comprehensive approach to health and wellness, enhancing quality of life and supporting long-term disease management
WADA 2026 Prohibited List Status (S2.2.3 Growth Hormone Fragments) AOD-9604 is named explicitly on the World Anti-Doping Agency 2026 Prohibited List under section S2.2.3 (Growth hormone, its analogs and fragments), prohibited at all times, both in-competition and out-of-competition
US$ 22.64
US$ 27.78
US$ 20.18
US$ 26.86
US$ 23.70
US$ 24.29
US$ 27.42
US$ 24.06
US$ 26.04
US$ 25.61
US$ 24.80
US$ 28.33
US$ 20.93
US$ 23.87
US$ 21.29
US$ 24.37
